Multidisciplinary strategies to treat severe hypoglycemia in hospitalized patients with diabetes mellitus reduce inpatient mortality rate: Experience from an academic community hospital
Kadayakkara D, Balasubramanian P, Araque K, Davis K, Javed F, Niaki P, Majumdar S, Buller G. Multidisciplinary strategies to treat severe hypoglycemia in hospitalized patients with diabetes mellitus reduce inpatient mortality rate: Experience from an academic community hospital. PLOS ONE 2019, 14: e0220956. PMID: 31393971, PMCID: PMC6687156, DOI: 10.1371/journal.pone.0220956.Peer-Reviewed Original ResearchConceptsPatient mortality ratesSevere hypoglycemiaReadmission ratesDiabetes mellitusMortality rateNotification ratesStandardized treatmentGeneral internal medicine wardsMultidisciplinary strategyPatient's medical teamInpatient mortality rateInternal medicine wardsICD-10 codesPost-intervention studyStandardization of treatmentGlucose measurementsAcademic community hospitalSame observation periodDiabetic patientsHospitalized patientsMedicine wardsRetrospective reviewPhysician notificationPoor outcomeSecondary diagnosisEmpagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?
Balasubramanian P, Wanner C, Ferreira J, Ofstad A, Elsaesser A, Zinman B, Inzucchi S. Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition? Medicine Of Ukraine 2022, 48-52. DOI: 10.37987/1997-9894.2022.5-6(261-2).271666.Peer-Reviewed Original ResearchIncidence rate ratiosT2D patientsClinical trialsStone eventsGLP-1 receptor agonistsLarge cardiovascular outcome trialsEMPA-REG OUTCOMESGLT2 inhibitor empagliflozinCardiovascular outcome trialsProspective clinical trialsSGLT2 inhibitor useRisk of nephrolithiasisAnnual incidence rateRandomized clinical trialsType 2 diabetesRelative risk estimatesEmpagliflozin therapyInhibitor empagliflozinInhibitor useOutcome trialsDiabetes mellitusSGLT2 inhibitionReceptor agonistRisk factorsIncidence rate